Nano-loaded human umbilical cord mesenchymal stem cells as targeted carriers of doxorubicin for breast cancer therapy

Cao, Shunxiu; Guo, Jiamin; He, Yujing; Alahdal, Murad; Tang, Shanshan; Zhao, Yuekui; Yang, Ziying; Gao, Huashan; Hu, Wenjun; Jiang, Hu‐Lin; Qin, Lianju; Jin, Liang

doi:10.1080/21691401.2018.1434185

Cited by 17 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Correspondingly, silica nanorattle-DOX-anchored MSCs sustained DOX intratumoral disseminations which led to significantly heightened tumor-cell apoptosis ( Li et al, 2011 ). Besides, human umbilical cord (UC)-MSCs carrying transferrin-inspired-nanoparticles containing DOX (hUC-MSC-Tf-inspired-NPs) displayed suitable potential of the secretion of Tf-inspired NPs, and also showed robust tumor tropism ( Cao et al, 2018 ). Importantly, investigations in MCF-7 breast tumor xenograft models indicated that hUC-MSC-Tf-inspired NPs could potently abrogate tumor growth, bringing novel anticancer drug delivery approach ( Cao et al, 2018 ).…”

Section: Msc-based Chemotherapeutic Agent Deliverymentioning

confidence: 99%

“…Besides, human umbilical cord (UC)-MSCs carrying transferrin-inspired-nanoparticles containing DOX (hUC-MSC-Tf-inspired-NPs) displayed suitable potential of the secretion of Tf-inspired NPs, and also showed robust tumor tropism ( Cao et al, 2018 ). Importantly, investigations in MCF-7 breast tumor xenograft models indicated that hUC-MSC-Tf-inspired NPs could potently abrogate tumor growth, bringing novel anticancer drug delivery approach ( Cao et al, 2018 ). Remarkably, other reports have shown that injection of DOX-loaded exosomes (Exo) derived from MSCs into an ectopic model of C26 (mouse colon adenocarcinoma) in BALB/c mice could support suppressed tumor growth in treated animals compared with those injected with DOX alone ( Bagheri et al, 2020 ).…”

Section: Msc-based Chemotherapeutic Agent Deliverymentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

Hassanzadeh

Altajer²,

Rahman

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mesenchymal stem/stromal cell (MSC)-based therapy has become an attractive and advanced scientific research area in the context of cancer therapy. This interest is closely linked to the MSC-marked tropism for tumors, suggesting them as a rational and effective vehicle for drug delivery for both hematological and solid malignancies. Nonetheless, the therapeutic application of the MSCs in human tumors is still controversial because of the induction of several signaling pathways largely contributing to tumor progression and metastasis. In spite of some evidence supporting that MSCs may sustain cancer pathogenesis, increasing proofs have indicated the suppressive influences of MSCs on tumor cells. During the last years, a myriad of preclinical and some clinical studies have been carried out or are ongoing to address the safety and efficacy of the MSC-based delivery of therapeutic agents in diverse types of malignancies. A large number of studies have focused on the MSC application as delivery vehicles for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), chemotherapeutic drug such as gemcitabine (GCB), paclitaxel (PTX), and doxorubicin (DOX), prodrugs such as 5-fluorocytosine (5-FC) and ganciclovir (GCV), and immune cell-activating cytokines along with oncolytic virus. In the current review, we evaluate the latest findings rendering the potential of MSCs to be employed as potent gene/drug delivery vehicle for inducing tumor regression with a special focus on the in vivo reports performed during the last two decades.

show abstract

Section: Msc-based Chemotherapeutic Agent Deliverymentioning

confidence: 99%

Section: Msc-based Chemotherapeutic Agent Deliverymentioning

confidence: 99%

RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

Hassanzadeh

Altajer²,

Rahman

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Doxorubicin loaded MSC were effective against breast and thyroid cancer in vitro and in vivo in mice[ 125 ] as well as in counteracting oral squamous cell carcinoma[ 126 ]. MSC exposure to nanoparticles with adsorbed doxorubicin was adopted as a strategy to control drug release: Such an approach was effective in reducing the proliferation of breast cancer, lung melanoma metastasis and glioblastoma in mice[ 127 , 128 ]. Purified exosomes obtained from doxorubicin loaded MSC were shown to be a potentially effective cell-free targeted therapy against osteosarcoma cells[ 129 ].…”

Section: Arming Msc Toward Cancermentioning

confidence: 99%

Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications

Vicinanza¹,

Lombardi²,

Ros³

et al. 2022

WJSC

View full text Add to dashboard Cite

Mesenchymal stem stromal cells (MSC) are characterized by the intriguing capacity to home toward cancer cells after systemic administration. Thus, MSC can be harnessed as targeted delivery vehicles of cytotoxic agents against tumors. In cancer patients, MSC based advanced cellular therapies were shown to be safe but their clinical efficacy was limited. Indeed, the amount of systemically infused MSC actually homing to human cancer masses is insufficient to reduce tumor growth. Moreover, induction of an unequivocal anticancer cytotoxic phenotype in expanded MSC is necessary to achieve significant therapeutic efficacy. Ex vivo cell modifications are, thus, required to improve anti-cancer properties of MSC. MSC based cellular therapy products must be handled in compliance with good manufacturing practice (GMP) guidelines. In the present review we include MSC-improving manipulation approaches that, even though actually tested at preclinical level, could be compatible with GMP guidelines. In particular, we describe possible approaches to improve MSC homing on cancer, including genetic engineering, membrane modification and cytokine priming. Similarly, we discuss appropriate modalities aimed at inducing a marked cytotoxic phenotype in expanded MSC by direct chemotherapeutic drug loading or by genetic methods. In conclusion, we suggest that, to configure MSC as a powerful weapon against cancer, combinations of clinical grade compatible modification protocols that are currently selected, should be introduced in the final product. Highly standardized cancer clinical trials are required to test the efficacy of ameliorated MSC based cell therapies.

show abstract

“…Some NPs, such as PAMAM dendrimers, silica NPs, and liposomes, may be suitable for improving drug retention in MSCs due to their low initial burst release. NPs loaded to MSCs are released extracellularly in an intact form via exocytosis and EVs [48,[110][111][112] or may only release the drug after disassembling the NPs in the cellular endosome/lysosome [112,113] (Figure 3). However, the drug delivery efficiency of NPloaded MSCs to tumor cells was not high.…”

Section: Msc Loading Of Anti-cancer Drugsmentioning

confidence: 99%

Mesenchymal stem/stromal cells as next-generation drug delivery vehicles for cancer therapeutics

Takayama

Kusamori

Nishikawa

2021

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction: Drug delivery to solid tumors remains a significant therapeutic challenge. Mesenchymal stem/stromal cells (MSCs) home to tumor tissues and can be employed as tumor targeted drug/gene delivery vehicles. Reportedly, therapeutic gene-or anti-cancer drug-loaded MSCs have shown remarkable anti-tumor effects in preclinical studies, and some clinical trials for assessing therapeutic MSCs in patients with cancer have been registered. Areas covered: In the present review, we first discuss the source and interdonor heterogeneity of MSCs, their tumor-homing mechanism, and the route of MSC administration in MSC-based cancer therapy. We then summarize the therapeutic applications of MSCs as a drug delivery vehicle for therapeutic genes or anti-cancer drugs and the drug delivery mechanism from drug-loaded MSCs to cancer cells. Expert opinion: Although numerous preclinical studies have revealed significant anti-tumor effects, several clinical trials assessing MSC-based cancer gene therapy have failed to demonstrate corroborative results, documenting limited therapeutic effects. Notably, a successful clinical outcome with MSC-based cancer therapy would require the interdonor heterogeneity of administered MSCs to be resolved, along with improved tumor-homing efficiency and optimized drug delivery efficiency from MSCs to cancer cells.

show abstract

Nano-loaded human umbilical cord mesenchymal stem cells as targeted carriers of doxorubicin for breast cancer therapy

Cited by 17 publications

References 40 publications

RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications

Mesenchymal stem/stromal cells as next-generation drug delivery vehicles for cancer therapeutics

Contact Info

Product

Resources

About